Phoenix Asia Holdings Reports H1 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Should l Buy PHOE?
Source: Newsfilter
- Revenue Decline: Total revenue for H1 2025 was $3,511,591, down 7.3% from $3,789,610 in H1 2024, primarily due to the completion of certain projects by March 31, 2025, which negatively impacted cash flow and market competitiveness.
- Significant Gross Profit Drop: Gross profit fell from $1,080,232 in 2024 to $741,443 in 2025, a decrease of 31.4%, mainly due to additional work necessitated by variation orders for certain projects, with amounts still under negotiation, potentially affecting future profitability.
- Net Income Plummets: Net income and total comprehensive income decreased by 68.6%, from $631,441 to $198,336, indicating severe challenges in profitability that could impact investor confidence and stock performance.
- Market Outlook: Despite financial challenges, the CEO expressed confidence in leveraging the company's experience and management expertise in substructure works to capture growth opportunities in Hong Kong's infrastructure market, signaling a commitment to future business expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHOE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHOE
About PHOE
Phoenix Asia Holdings Ltd is an investment holding company mainly engaged in the substructure works business. The Company is mainly engaged in site formation, ground investigation and foundation works business as subcontractor. The Company also provides other construction services such as structural steelworks, advisory services and supervision services in substructure projects.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ACEA Therapeutics to be Acquired by Phoenix Asia in $1 Billion Deal
- Deal Details: ACEA Therapeutics will sell 100% of its equity interests in ACEA Pharma to Phoenix Asia for a total transaction value of $1 billion, with Phoenix issuing 100 million new ordinary shares at $10 each, expected to close by Q2 2026, marking a significant shift towards the pharmaceutical industry.
- Stock Price Reaction: Shares of Phoenix Asia Holdings (PHOE) surged 169% following the announcement of the deal, reflecting strong market optimism and the potential for further growth in the pharmaceutical sector.
- Market Sentiment: On Stocktwits, retail sentiment around SCLX remained in the 'extremely bullish' territory, while PHOE's sentiment jumped from 'bullish' to 'extremely bullish', indicating positive investor reactions and expectations for future potential.
- Corporate Restructuring: Upon completion of the deal, Phoenix Asia will be renamed ACEA Pharma, Inc., continuing to trade on Nasdaq, with ACEA Therapeutics projected to own approximately 82% of the new entity, further solidifying its position in the pharmaceutical industry.
See More
Scilex Acquires ACEA Pharma for $1 Billion
- Acquisition Overview: Scilex's indirect subsidiary ACEA Therapeutics has entered into an agreement with Phoenix Asia Holdings to sell 100% of ACEA Pharma's equity interests at $10 per share, totaling $1 billion, with completion expected by the end of Q2 2026, marking a strategic expansion in non-opioid pain management.
- Equity Structure Change: Upon closing, ACEA Therapeutics anticipates owning approximately 82% of the newly formed ACEA Pharma, enhancing its market control and supporting future product development and commercialization efforts.
- Market Listing Plans: The newly established ACEA Pharma is expected to be listed on Nasdaq, which will not only elevate the company's market visibility but also potentially attract more investor interest in its non-opioid pain management products, further driving company growth.
- Strategic Implications: This acquisition aligns with Scilex's long-term growth strategy and will enhance its competitive position in the acute and chronic pain treatment market by integrating ACEA Pharma's R&D capabilities to meet the increasing patient demand.
See More
SCILEX HOLDING CO - ACEA THERA TO ACQUIRE APPROXIMATELY 82% OF THE CONTINUING COMPANY AFTER CLOSURE
Company Overview: Cilex Holding Co. has a significant stake in the Go-Forward Company, owning approximately 82% of it.
Recent Developments: The ownership stake was confirmed upon the closing of a recent transaction.
See More
SCILEX HOLDING CO - PHOENIX TO CHANGE NAME TO ACEA PHARMA, INC. AND PLANS TO DEBUT ON NASDAQ
- Company Name Change: SciLEx Holding Co. is set to be renamed as Acea Pharma, Inc.
- Upcoming Listing: The company is expected to list on the NASDAQ stock exchange.
See More
SCILEX HOLDING CO - ACEA THERA TO DIVEST ENTIRE STAKE IN ACEA PHARMA TO PHOENIX FOR $1 BILLION IN STOCK
Acquisition Announcement: Cilex Holding Co. has announced the sale of its subsidiary, Acea, which includes 100% of the shares of Acea Pharma.
Transaction Value: The deal is valued at $1 billion, indicating a significant financial move in the pharmaceutical sector.
See More
SCILEX HOLDING COMPANY REVEALS SUBSIDIARIES ACEA THERAPEUTICS, INC. AND ACEA PHARMA, INC. HAVE SIGNED A DEFINITIVE AGREEMENT WITH PHOENIX ASIA HOLDINGS LIMITED
Announcement of Agreement: SciLEx Holding Company has announced a definitive agreement with Phoenix Asia Holdings Limited.
Subsidiaries Involved: The agreement involves SciLEx's subsidiaries, Acea Therapeutics, Inc. and Acea Pharma, Inc.
See More
ACEA Therapeutics to be Acquired by Phoenix Asia in $1 Billion Deal
- Deal Details: ACEA Therapeutics will sell 100% of its equity interests in ACEA Pharma to Phoenix Asia for a total transaction value of $1 billion, with Phoenix issuing 100 million new ordinary shares at $10 each, expected to close by Q2 2026, marking a significant shift towards the pharmaceutical industry.
- Stock Price Reaction: Shares of Phoenix Asia Holdings (PHOE) surged 169% following the announcement of the deal, reflecting strong market optimism and the potential for further growth in the pharmaceutical sector.
- Market Sentiment: On Stocktwits, retail sentiment around SCLX remained in the 'extremely bullish' territory, while PHOE's sentiment jumped from 'bullish' to 'extremely bullish', indicating positive investor reactions and expectations for future potential.
- Corporate Restructuring: Upon completion of the deal, Phoenix Asia will be renamed ACEA Pharma, Inc., continuing to trade on Nasdaq, with ACEA Therapeutics projected to own approximately 82% of the new entity, further solidifying its position in the pharmaceutical industry.
See More
Scilex Acquires ACEA Pharma for $1 Billion
- Acquisition Overview: Scilex's indirect subsidiary ACEA Therapeutics has entered into an agreement with Phoenix Asia Holdings to sell 100% of ACEA Pharma's equity interests at $10 per share, totaling $1 billion, with completion expected by the end of Q2 2026, marking a strategic expansion in non-opioid pain management.
- Equity Structure Change: Upon closing, ACEA Therapeutics anticipates owning approximately 82% of the newly formed ACEA Pharma, enhancing its market control and supporting future product development and commercialization efforts.
- Market Listing Plans: The newly established ACEA Pharma is expected to be listed on Nasdaq, which will not only elevate the company's market visibility but also potentially attract more investor interest in its non-opioid pain management products, further driving company growth.
- Strategic Implications: This acquisition aligns with Scilex's long-term growth strategy and will enhance its competitive position in the acute and chronic pain treatment market by integrating ACEA Pharma's R&D capabilities to meet the increasing patient demand.
See More
SCILEX HOLDING CO - ACEA THERA TO ACQUIRE APPROXIMATELY 82% OF THE CONTINUING COMPANY AFTER CLOSURE
Company Overview: Cilex Holding Co. has a significant stake in the Go-Forward Company, owning approximately 82% of it.
Recent Developments: The ownership stake was confirmed upon the closing of a recent transaction.
See More
SCILEX HOLDING CO - PHOENIX TO CHANGE NAME TO ACEA PHARMA, INC. AND PLANS TO DEBUT ON NASDAQ
- Company Name Change: SciLEx Holding Co. is set to be renamed as Acea Pharma, Inc.
- Upcoming Listing: The company is expected to list on the NASDAQ stock exchange.
See More
SCILEX HOLDING CO - ACEA THERA TO DIVEST ENTIRE STAKE IN ACEA PHARMA TO PHOENIX FOR $1 BILLION IN STOCK
Acquisition Announcement: Cilex Holding Co. has announced the sale of its subsidiary, Acea, which includes 100% of the shares of Acea Pharma.
Transaction Value: The deal is valued at $1 billion, indicating a significant financial move in the pharmaceutical sector.
See More
SCILEX HOLDING COMPANY REVEALS SUBSIDIARIES ACEA THERAPEUTICS, INC. AND ACEA PHARMA, INC. HAVE SIGNED A DEFINITIVE AGREEMENT WITH PHOENIX ASIA HOLDINGS LIMITED
Announcement of Agreement: SciLEx Holding Company has announced a definitive agreement with Phoenix Asia Holdings Limited.
Subsidiaries Involved: The agreement involves SciLEx's subsidiaries, Acea Therapeutics, Inc. and Acea Pharma, Inc.
See More
